Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
COLUMN
Maurer's Healthcare Insight (Special)
Japan's Most Admired Pharma Companies In 2002P. Reed MaurerSince 1999 Nippon Pharma Promotion (NPP) has conducted annual surveys among three groups of people: employees of pharmaceutical manufacturers, wholesaler personnel, and service providers to the industry. The objective is to determine…
To read the full story
COLUMN
- Elevating Leadership: Insights from Japan’s Healthcare Sector
October 23, 2024
- 6 Tips for Motivating and Engaging Current Employees
September 30, 2024
- Why LinkedIn Isn’t Effective in Japan
August 27, 2024
- The Dynamics of Field Medical Visits: Importance of Balancing Quality and Frequency in Medical Interactions
August 2, 2024
- 3 Common Mistakes Made when Hiring a Leader
July 25, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…